With an increasing prevalence during the past decades, atopic dermatitis has become a
global health issue. A literature search following a targeted approach was undertaken to …

Health disparities are health differences linked with economic, social, and environmental
disadvantage. They adversely affect groups that have systematically experienced greater …

Background Tralokinumab is a fully human monoclonal antibody that specifically neutralizes
interleukin‐13, a key driver of atopic dermatitis (AD). Objectives To evaluate the efficacy and …

Background Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier
function. Objective Evaluate interleukin 22 blockade in adults with moderate-to-severe …

Importance Atopic dermatitis is associated with substantial patient and caregiver burden.
Currently available treatments for atopic dermatitis are inadequate or contraindicated for …

Background Significant unmet need exists for long-term treatment of moderate to severe
atopic dermatitis (AD). Objective To assess the long-term safety and efficacy of dupilumab in …

Background Moderate‐to‐severe atopic dermatitis (AD) often requires long-term
management with systemic therapies. Objective Our objective was to report the safety and …

Background GBR 830 is a humanized mAb against OX40, a costimulatory receptor on
activated T cells. OX40 inhibition might have a therapeutic role in T cell–mediated diseases …

Background Patients with moderate-to-severe atopic dermatitis (AD) have increased
infection risk, including skin infections and systemic infections. Immunomodulators (eg, anti …

Atopic dermatitis (AD) is a skin disease that is heterogeneous both in terms of clinical
manifestations and molecular profiles. It is increasingly recognized that AD is a systemic …